PriceTargets.com logo

NASDAQ:SWAV - ShockWave Medical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $109.50
  • Forecasted Upside: -6.22 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$116.76 As of 02/26/2021 01:00 AM ET
▲ +0.22 (0.19%)
1 month | 3 months | 12 months
Get New ShockWave Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SWAV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SWAV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$109.50
▼ -6.22% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for ShockWave Medical in the last 3 months. The average price target is $109.50, with a high forecast of $134.00 and a low forecast of $23.00. The average price target represents a -6.22% upside from the last price of $116.76.
Hold
The current consensus among 6 polled investment analysts is to hold stock in ShockWave Medical. This rating has held steady since January 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/6/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021Piper SandlerBoost Price TargetNeutral$132.00 ➝ $134.00High
i
2/25/2021Morgan StanleyBoost Price TargetEqual Weight$103.00 ➝ $130.00High
i
2/18/2021Piper SandlerBoost Price TargetNeutral$132.00 ➝ $134.00High
i
2/2/2021Canaccord GenuityBoost Price TargetBuy$87.00 ➝ $131.00Low
i
1/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$96.00 ➝ $132.00High
i
1/12/2021Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $134.00High
i
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$89.00 ➝ $103.00Low
i
12/1/2020Bank of AmericaDowngradeBuy ➝ Neutral$105.00High
i
11/11/2020Morgan StanleyBoost Price TargetEqual Weight$72.00 ➝ $89.00Low
i
11/10/2020Wells Fargo & CompanyBoost Price TargetOverweight$90.00 ➝ $95.00High
i
11/10/2020Piper SandlerBoost Price TargetOverweight$86.00 ➝ $93.00High
i
10/19/2020Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $72.00Medium
i
10/16/2020Canaccord GenuityBoost Price TargetBuy$60.00 ➝ $87.00High
i
10/16/2020Wells Fargo & CompanyBoost Price TargetOverweight$80.00 ➝ $90.00High
i
10/16/2020Piper SandlerBoost Price TargetOverweight$76.00 ➝ $86.00High
i
9/18/2020Wells Fargo & CompanyBoost Price TargetPositive ➝ Overweight$59.00 ➝ $80.00High
i
9/15/2020Piper SandlerBoost Price Target$58.00 ➝ $76.00Medium
i
8/12/2020Morgan StanleyBoost Price TargetEqual Weight$42.00 ➝ $55.00High
i
8/12/2020Piper SandlerBoost Price TargetOverweight$54.00 ➝ $58.00High
i
8/12/2020Canaccord GenuityBoost Price TargetBuy$53.00 ➝ $60.00Low
i
7/8/2020OppenheimerInitiated CoverageHoldHigh
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
6/11/2020OppenheimerUpgradeUnderperform ➝ Market PerformHigh
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
6/9/2020Canaccord GenuityBoost Price TargetBuy$46.00 ➝ $53.00Medium
i
6/9/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $54.00High
i
Rating by Adam Maeder at Piper Sandler
5/13/2020Morgan StanleyBoost Price TargetEqual Weight$40.00 ➝ $42.00High
i
5/13/2020Canaccord GenuityReiterated RatingBuy$53.00 ➝ $46.00High
i
5/13/2020Wells Fargo & CompanyBoost Price TargetBuy$43.00 ➝ $46.00High
i
Rating by Larry Biegelsen at Wells Fargo & Company
5/12/2020OppenheimerInitiated CoverageSell$23.00High
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
4/21/2020Piper SandlerLower Price TargetOverweight$54.00 ➝ $45.00High
i
Rating by Adam Maeder at Piper Sandler
4/1/2020OppenheimerDowngradeMarket Perform ➝ Underperform$23.00High
i
3/27/2020Morgan StanleyLower Price TargetEqual Weight$51.00 ➝ $40.00Medium
i
2/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$47.00 ➝ $50.00High
i
2/14/2020Piper SandlerBoost Price Target$50.00 ➝ $54.00Low
i
Rating by Adam Maeder at Piper Sandler
1/23/2020Piper SandlerReiterated RatingBuy$48.00Low
i
Rating by Adam Maeder at Piper Sandler
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$35.00 ➝ $47.00Low
i
12/12/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Overweight$49.00High
i
12/11/2019Piper Jaffray CompaniesBoost Price TargetOverweight$43.00 ➝ $46.00High
i
Rating by Adam Maeder at Piper Jaffray Companies
11/8/2019Canaccord GenuityLower Price TargetBuy$65.00 ➝ $49.00High
i
11/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$39.00 ➝ $43.00High
i
Rating by Adam Maeder at Piper Jaffray Companies
10/22/2019OppenheimerInitiated CoverageMarket PerformHigh
i
10/21/2019Piper Jaffray CompaniesInitiated CoverageOverweight$39.00High
i
6/18/2019Canaccord GenuityBoost Price TargetBuy ➝ Positive$50.00 ➝ $65.00Low
i
6/13/2019Bank of AmericaReiterated RatingNeutral$44.00Low
i
4/1/2019Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market Perform$33.00Low
i
4/1/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$37.00Low
i
4/1/2019Morgan StanleyInitiated CoverageEqual Weight ➝ Equal Weight$32.00Low
i
(Data available from 2/28/2016 forward)
ShockWave Medical logo
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: $116.76
$112.65
$120.35

50 Day Range

MA: $127.08
$116.04
$142.05

52 Week Range

Now: $116.76
$22.01
$143.79

Volume

401,144 shs

Average Volume

419,746 shs

Market Capitalization

$4.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of ShockWave Medical?

The following sell-side analysts have issued research reports on ShockWave Medical in the last twelve months: Bank of America Co., Canaccord Genuity, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for SWAV.

What is the current price target for ShockWave Medical?

6 Wall Street analysts have set twelve-month price targets for ShockWave Medical in the last year. Their average twelve-month price target is $109.50, suggesting a possible downside of 6.2%. Wells Fargo & Company has the highest price target set, predicting SWAV will reach $134.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $23.00 for ShockWave Medical in the next year.
View the latest price targets for SWAV.

What is the current consensus analyst rating for ShockWave Medical?

ShockWave Medical currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SWAV, but not buy more shares or sell existing shares.
View the latest ratings for SWAV.

What other companies compete with ShockWave Medical?

Other companies that are similar to ShockWave Medical include NovoCure, Abiomed, Penumbra, Hill-Rom, Haemonetics, Inspire Medical Systems, Globus Medical, Tandem Diabetes Care, Integra LifeSciences, Nevro, Inari Medical, iRhythm Technologies, ICU Medical, Glaukos and Cantel Medical.

How do I contact ShockWave Medical's investor relations team?

ShockWave Medical's physical mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company's listed phone number is 510-279-4262 and its investor relations email address is [email protected] The official website for ShockWave Medical is www.shockwavemedical.com.